肺癌化疗过程中4种止吐方案的成本-效果分析  

Cost-Effectiveness Analysis of Four Antiemetic Schemes for Patients with Lung Cancer Treated with Chemotherapy

作　　者：蔡旭镇[1] 林晓华[1] 黄丽娜[1] 郑潮标[1] 

机构地区：[1]广东揭阳市人民医院,揭阳市522000

出　　处：《中国药房》2009年第2期90-92,共3页China Pharmacy

摘　　要：目的:比较4种止吐方案对预防肺癌化疗所致呕吐的成本-效果。方法:对120例接受含顺铂化疗的肺癌患者分为4组,分别用昂丹司琼(A组)、托烷司琼(B组)、雷莫司琼(C组)、甲氧氯普胺(D组)预防化疗所致呕吐,观察其疗效并进行成本-效果分析。结果:4组止吐有效率分别为87.3%、92.7%、90.7%、61.3%,成本-效果比分别为684.77、906.37、222.33、45.02;以D组为参照,A、B、C组的增量成本-效果比分别为2193.08、2587.90、592.01。结论:应用雷莫司琼是较为合理的治疗方案。OBJECTIVE： To compare the cost- effectiveness among four different antiemetic schemes for prevention vomiting induced by chemotherapy in patients with lung cancer. METHODS： 120 patients receiving cisplatin chemotherapy were divided into 4 groups： Ondansetron （Group A）, Tropisetron （Group B）, Ramosetron （Group C）, and Metoclopramide （Group D） . The therapeutic effects were monitored and the cost - effectiveness analysis was performed on the four treatment schemes. RESULTS： The effective rates of the four groups were 87.a%, 92.7%, 90.7% and 61.3% respectively; the cost effectiveness ratios were 684.77, 906.37, 222.33 and 45.02, respectively; and the incremental cost - effectiveness ratios of A, B and C group were 2 193.08, 2 587.90 and 592.01 respectively as against Group D. CONCLUSION： Ramosetron is the most rational one among the 4 schemes. s

关 键 词：肺癌 化疗 呕吐 成本-效果分析 

分 类 号：R730.53[医药卫生—肿瘤] F407.7[医药卫生—临床医学]